Welcome to our dedicated page for ABEONA THERAPEUTICS SEC filings (Ticker: ABEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ABEONA THERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ABEONA THERAPEUTICS's regulatory disclosures and financial reporting.
Abeona Therapeutics director Eric Crombez received a new equity grant. On January 26, 2026, he was awarded 37,313 shares of Abeona Therapeutics common stock as restricted stock at a price of $0.00 per share. After this grant, he directly owns 79,740 common shares.
The filing states that all of this restricted stock will vest on January 26, 2027, meaning the shares become fully earned on that date if vesting conditions are satisfied.
Abeona Therapeutics director receives restricted stock grant. Director Christine Silverstein Berni was awarded 37,313 shares of Abeona Therapeutics common stock on January 26, 2026 at a price of $0.00 per share. All of this restricted stock will vest on January 26, 2027.
Following this grant, she beneficially owns 157,792 shares of Abeona Therapeutics common stock in direct ownership.
Abeona Therapeutics director Michael Amoroso received a stock grant. On January 26, 2026, he was awarded 37,313 shares of Abeona Therapeutics common stock at a price of $0.00 per share as restricted stock. After this grant, he beneficially owned 217,779 shares directly. All of the restricted stock is scheduled to vest on January 26, 2027.
Abeona Therapeutics director Faith L. Charles received an equity grant of 37,313 shares of common stock as restricted stock on January 26, 2026. The award was reported at a price of $0.00 per share, reflecting a stock-based compensation grant rather than an open-market purchase.
Following this grant, Charles beneficially owns 176,407 shares of Abeona common stock in direct form. All of the restricted stock from this award is scheduled to vest on January 26, 2027, aligning her compensation with the company’s future performance over the vesting period.
Abeona Therapeutics director Mark Alvino received a grant of 37,313 shares of common stock on January 26, 2026, at a price of $0.00 per share. These are restricted shares that will fully vest on January 26, 2027. Following this award, he beneficially owns 86,065 shares directly.
Abeona Therapeutics Inc. director Leila Alland received a grant of 37,313 shares of common stock on January 26, 2026 at a price of $0.00 per share. This reflects an equity-based award rather than a cash purchase.
All of the restricted stock is scheduled to vest on January 26, 2027. Following this grant, Alland beneficially owns 191,679 shares of Abeona common stock in direct ownership, according to the filing.
Abeona Therapeutics Chief Commercial Officer Vasanthavada Madhav reported a new stock grant and a related share sale. On January 20, 2026, he received 76,621 shares of restricted common stock at $0.00, which will vest in three equal parts on January 20, 2027, January 20, 2028, and January 20, 2029. On January 22, 2026, he sold 12,610 shares of common stock at a weighted average price of $5.2861 per share to cover tax obligations from restricted stock vesting. After these transactions, he directly beneficially owned 318,619 shares of Abeona common stock.
Abeona Therapeutics’ Chief Commercial Officer, Madhav Vasanthavada, has reported his initial beneficial ownership in the company’s stock. He directly holds 254,608 shares of common stock, which include 176,384 shares of unvested restricted stock scheduled to vest on various dates between January 21, 2026 and January 21, 2028.
He also holds an employee stock option to purchase 2,400 shares of common stock at an exercise price of $4.00 per share, expiring on June 15, 2032. This option became exercisable as to 600 shares on June 15, 2023 and then in 36 equal monthly installments thereafter, providing a gradual vesting schedule over time.
Abeona Therapeutics’ Chief Financial Officer Joseph Walter Vazzano sold 18,666 shares of common stock on January 22, 2026 at a weighted average price of $5.3309 per share. The filing explains that this sale was made to cover tax obligations tied to the vesting of restricted stock awards, meaning it was related to compensation rather than an open-market liquidation of a large personal position.
After this tax-related sale, Vazzano beneficially owned 568,560 shares of Abeona common stock directly. The reported price reflects multiple trades in a range from $5.33 to $5.38 per share, aggregated into a single weighted average figure in the filing.
Abeona Therapeutics CEO Vishwas Seshadri, who also serves as a director, reported a sale of company common stock. On January 22, 2026, he sold 69,832 shares of Abeona Therapeutics common stock in an open market transaction coded as a sale. The shares were sold at a weighted average price of $5.3309 per share, through multiple trades at prices ranging from $5.33 to $5.38.
According to the filing, this sale was made to cover tax obligations associated with the vesting of restricted stock awards. After the transaction, Seshadri beneficially owned 1,460,408 shares of Abeona Therapeutics common stock directly.